| Primary |
| Acute Myeloid Leukaemia |
20.5% |
| Acute Lymphocytic Leukaemia |
19.0% |
| B-cell Type Acute Leukaemia |
7.2% |
| Lymphoma |
7.2% |
| Diffuse Large B-cell Lymphoma |
6.7% |
| Acute Myeloblastic Leukemia |
4.6% |
| Acute Myeloid Leukemia |
4.6% |
| Central Nervous System Lymphoma |
4.6% |
| T-cell Type Acute Leukaemia |
4.6% |
| Non-hodgkin's Lymphoma |
4.1% |
| Chemotherapy |
3.6% |
| Nausea |
2.6% |
| Bone Marrow Transplant |
2.1% |
| Burkitt's Lymphoma |
1.5% |
| Chemotherapy Antiemetic Prophylaxis |
1.5% |
| Chronic Myeloid Leukaemia |
1.5% |
| Acute Myelomonocytic Leukaemia |
1.0% |
| Antibiotic Therapy |
1.0% |
| Antifungal Prophylaxis |
1.0% |
| Anxiodepressive Syndrome |
1.0% |
|
| Cerebellar Syndrome |
11.8% |
| Septic Shock |
8.8% |
| Status Epilepticus |
8.8% |
| Toxic Skin Eruption |
8.8% |
| Aspergillosis |
5.9% |
| Encephalopathy |
5.9% |
| Lung Infiltration |
5.9% |
| Sepsis |
5.9% |
| Thrombocytopenia |
5.9% |
| Acute Coronary Syndrome |
2.9% |
| Acute Febrile Neutrophilic Dermatosis |
2.9% |
| Aplasia |
2.9% |
| Bone Marrow Failure |
2.9% |
| Bronchopulmonary Aspergillosis |
2.9% |
| Cardiac Failure Acute |
2.9% |
| Encephalitis |
2.9% |
| Febrile Bone Marrow Aplasia |
2.9% |
| Hepatitis |
2.9% |
| Hepatocellular Injury |
2.9% |
| Herpes Zoster |
2.9% |
|
| Secondary |
| Acute Myeloid Leukaemia |
22.8% |
| Product Used For Unknown Indication |
11.4% |
| Drug Use For Unknown Indication |
10.6% |
| Acute Lymphocytic Leukaemia |
10.1% |
| Bone Marrow Conditioning Regimen |
7.8% |
| Mantle Cell Lymphoma |
4.9% |
| Pyrexia |
4.4% |
| Lymphoma |
4.2% |
| Diffuse Large B-cell Lymphoma |
3.8% |
| Bronchopulmonary Aspergillosis |
3.4% |
| B-cell Type Acute Leukaemia |
2.5% |
| Drug Exposure During Pregnancy |
2.2% |
| Bone Pain |
1.9% |
| T-cell Type Acute Leukaemia |
1.5% |
| B-cell Lymphoma |
1.5% |
| Non-hodgkin's Lymphoma |
1.5% |
| Leukaemia |
1.5% |
| Premedication |
1.4% |
| Prophylaxis |
1.4% |
| Chronic Myeloid Leukaemia |
1.2% |
|
| Pancreatitis Acute |
10.8% |
| Ventricular Fibrillation |
8.8% |
| Febrile Bone Marrow Aplasia |
8.3% |
| Thrombocytopenia |
7.8% |
| Toxic Skin Eruption |
7.4% |
| Pyrexia |
6.4% |
| Venoocclusive Liver Disease |
5.4% |
| Axonal Neuropathy |
4.9% |
| Bronchopulmonary Aspergillosis |
3.9% |
| Myocardial Infarction |
3.9% |
| Renal Failure |
3.9% |
| Vasculitis Cerebral |
3.9% |
| Sepsis |
3.4% |
| Venoocclusive Disease |
3.4% |
| Posterior Reversible Encephalopathy Syndrome |
2.9% |
| Renal Failure Acute |
2.9% |
| Respiratory Distress |
2.9% |
| Septic Shock |
2.9% |
| Tremor |
2.9% |
| Vomiting |
2.9% |
|
| Concomitant |
| Acute Lymphocytic Leukaemia |
14.9% |
| B-cell Lymphoma |
11.4% |
| Drug Use For Unknown Indication |
11.4% |
| Product Used For Unknown Indication |
11.2% |
| Acute Myeloid Leukaemia |
9.8% |
| Prophylaxis |
4.7% |
| Bone Marrow Conditioning Regimen |
4.3% |
| Chemotherapy |
4.3% |
| Lymphocytic Leukaemia |
3.7% |
| Pyrexia |
3.7% |
| Cord Blood Transplant Therapy |
3.1% |
| Non-hodgkin's Lymphoma |
2.9% |
| Hyperthermia |
2.7% |
| Chronic Myeloid Leukaemia |
2.5% |
| Hypertension |
2.0% |
| Lymphoma |
1.8% |
| T-cell Type Acute Leukaemia |
1.8% |
| Staphylococcal Sepsis |
1.6% |
| Acute Myeloid Leukaemia Recurrent |
1.2% |
| Antibiotic Prophylaxis |
1.2% |
|
| Vomiting |
9.5% |
| White Blood Cell Count Decreased |
9.5% |
| Stem Cell Transplant |
8.3% |
| Pyrexia |
7.1% |
| Weight Decreased |
7.1% |
| Pleural Effusion |
6.0% |
| Shock |
6.0% |
| Venoocclusive Liver Disease |
6.0% |
| Renal Failure Acute |
4.8% |
| Sepsis |
4.8% |
| Septic Shock |
4.8% |
| Agranulocytosis |
3.6% |
| Rash |
3.6% |
| Respiratory Distress |
3.6% |
| Toxicity To Various Agents |
3.6% |
| Drug Reaction With Eosinophilia And Systemic Symptoms |
2.4% |
| Gamma-glutamyltransferase Increased |
2.4% |
| Hypersensitivity Vasculitis |
2.4% |
| Liver Disorder |
2.4% |
| Lung Disorder |
2.4% |
|
